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OBJECTIVES: Several international studies suggest that the time between symp-
tom onset and DMARD initiation in RA patients is longer than is considered opti-
mal. We sought to assess the health economic impact of this delay in an Australian
context. METHODS: The delay in DMARD initiation was estimated from a 2005
study of 96 Australian RA patients referred to one public and four private rheuma-
tology practices. RA-associated utilities and costs were sourced from published
data. Patients not taking and taking DMARD therapy were assumed to have utilities
of 0.443 and 0.543, respectively. The annual direct costs of RA, excluding DMARDs,
was AUD $3780, and of DMARD therapy was $2658. It was conservatively assumed
that DMARD therapy did not reduce non-DMARD RA costs. RESULTS: In the 2005
study, the mean time from symptom onset to initiation of DMARD therapy was 1.48
years. Over this time a mean of 0.65 QALYs would have been lived per patient and
$5579 of direct health care costs incurred. Had DMARDs been commenced at symp-
tom onset, 0.80 QALYs would have been lived per patient, and $9503 of direct health
care costs incurred. Hence early initiation of DMARDs would have saved 0.15
QALYs at a cost of $3924 per person, equating to an incremental cost-effectiveness
ratio (ICER) of $26,583 per QALY saved. An additional $3400 could be spent per
patient to reduce the time to DMARD initiation before the ICER breached the arbi-
trary cut-off of $50,000 per QALY saved. Our analysis was conservative in it did not
consider the long-term health and cost savings associated with avoidance of per-
manent joint damage. CONCLUSIONS: The considerable delay in the initiation of
DMARD therapy among patients with RA leads to significant health loss. Reducing
the time to initiation of DMARDs represents a cost-effective means of reducing the
burden of RA.
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OBJECTIVES: To evaluate the cost-effectiveness of monotherapy TCZ in DMARD-IR
patients intolerant of or contraindicated to MTX in the United Kingdom (UK).
METHODS: An economic model was developed to reflect the health care system
and treatment pathway in the UK. In the model, disease severity is represented by
the health assessment questionnaire (HAQ) score; a surrogate health outcome
which can be translated to utility scores and ultimately quality adjusted life years
(QALYs). The model captures the progression of the HAQ score for each individual
patient. Benefits were expressed as QALYs. Costs were calculated from a National
Health Service and Personal Social Services perspective. The analysis calculated
incremental costs and benefits associated with the addition of TCZ in first line to
the standard care pathway involving certolizumab pegol, etanercept and adali-
mumab. Efficacy data for comparator biologic monotherapies were available from
monotherapy trials of adalimumab (van de Putte et al 2004), certolizumab pegol
(Fleischmann et al 2009), and etanercept (Moreland et al 1999). TCZ efficacy was
informed by results from the ADACTA study (Gabay et al 2012), a new head-to-head
superiority trial of TCZ and adalimumab monotherapy in RA. The economic model
used inputs derived through a mixed treatment comparison that indirectly com-
pared TCZ monotherapy with the standard of care biologic monotherapy treat-
ments used in the UK (Roche data on file). RESULTS: Base case results estimated
incremental costs of approximately £20,230 and incremental QALYs of 0.88. The
incremental cost-effectiveness ratio (ICER) was £22,950 per QALY gained. A proba-
bilistic sensitivity analysis produced a very similar ICER of £23,200 per QALY
gained. CONCLUSIONS: The results of this analysis suggest that TCZ monotherapy
represents an efficacious and cost-effective addition to the current standard of care
in the UK, for treating RA patients who are intolerant of or contraindicated to MTX.
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OBJECTIVES: Etanercept and infliximab are two mostly used biologic disease-
modifying anti-rheumatic drugs (DMARDs) for the management of rheumatoid
arthritis (RA). The aim of this study was to compare the clinical and economic
consequences of using either etanercept or infliximab in the management of RA
in Spain. METHODS: A decision analytic model was built to combine trial-based
outcomes and costs of compared options. Efficacy data was obtained from an over-
view of Cochrane reviews. Newer therapies in the analysis, other than etanercept
and infliximab, were not included because of methodological differences and pa-
tients characteristics of their corresponding clinical trials. Different approaches
and data sources were used to estimate QALYs from trial-based ACR outcomes and
local Spanish health care costs were used to model the economic consequences of
RA treatment for a 1-year period. Probabilistic and univariate sensitivity analyses
were performed to test different dose titration, vial waste assumptions and patient
weight. RESULTS: Etanercept was associated to 0.033 - 0.042 QALYs gained depend-
ing on different sources to convert ACR outcomes to utilities. Model results showed
that etanercept was a dominant option (cost savings of 573 € - 10,004 € depending
on patients weight) with respect to infliximab in all studied weight scenarios with-
out dose titration when vial wasting was considered. The results of the sensitivity
analyses showed that when no vial wasting was considered, etanercept was a
dominant option in patients weighing  90 Kg, and an overall cost-effective alter-
native for all other patients weights. When considering doses used in daily clinical
practice with infliximab dose titration, etanercept was a dominant option in all
patient weight groups. CONCLUSIONS: The results of this study show that etaner-
cept may improve RA outcomes at no extra cost under different circumstances or
with an extra cost yielding to iCERs below commonly accepted thresholds in most
scenarios.
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OBJECTIVES: To estimate indirect costs of RA in Serbia, related to work absentee-
ism, medical welfare and rehabilitation in specialized centers. METHODS: Repre-
sentative group of 90 general practitioners (GPs) collected the data in period 01/01/
2011-31/12/2011 and from records evaluated their RA patients. They collected the
data on frequency of RA patients in their practice in 2011, their working ability and
absenteeism, diagnostic procedures, treatment and usage of specialized rehabili-
tation and different kinds of government provided welfares. Absenteeism costs
were calculated through mean of average salary in Serbia (as average cost of work-
ing day lost), rehabilitation (as average cost of one day treatment in outpatient or
hospitalized specialized rehabilitation center) and medical welfare costs were cal-
culated through official price list of respective public funds for these services. The
costs were extrapolated to official demographic population data of Serbia.
RESULTS: Based on this study, frequencies of employed, unemployed and retired
RA patients in Serbia are 23% (8,089 patients), 22% (7,737 patients), and 55% (19,344
patients) out of 35,168 respectively. Among small number of employed patients,
average duration of work absenteeism due to RA is 33.7 days, and cumulative
annual work absenteeism equals 272,599 days, with costs of 7.77 mio EUR. Medical
welfare is used by 13% (4,572) RA patients, with costs of 7.3 mio. EUR. Rehabilitation
in specialized centers at least once per year is used by 48% (16,882) RA patients,
average treatment lasts for 21 days, with costs of 10.03 mio EUR. CONCLUSIONS:
Unemployment among RA patients is very high in Serbia while indirect costs re-
lated to work absenteeism, rehabilitation in specialized centers and medical wel-
fare usage in Serbia are high (25 mio EUR), as well. Further detailed analyses of RA
patients economic burden is necessary in order to improve treatment approach
and lower state expenses.
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OBJECTIVES: To assess and compare the impact of rheumatoid arthritis (RA), an-
kylosing spondylitis (AS) and psoriasis (Ps) on work productivity, to estimate pro-
ductivity costs in the Czech Republic and to evaluate the effect of functional status
and disease activity on productivity costs. METHODS: According to Work Produc-
tivity and Activity Impairment Questionnaire was assessed productivity loss of
patients with RA (n77), AS (n230), Ps (n93) in productive age. Patient-reported
outcome (PRO) (HAQ, BASDAI) and clinical parameters (DAS28, BSA, PASI) were also
included. The interdependence among PROs and overall work productivity loss or
productivity costs were described by Spearman=s rank correlation coefficient. Pro-
ductivity costs were calculated by friction cost approach. RESULTS: Average pa-
tients age was 47.1 years (22-62) and average disease duration 15.7 years. Patients
with RA revealed higher HAQ (1.22) compared to AS patients (1.00). Mean DAS28 of
RA patients was 5.58 and mean BASDAI of AS patients was 4.43. Mean BSA and PASI
for Ps patients were 21.09% and 12.85. The percentage of psoriatic arthritis (Ps
patients) was 24.7%. We did not reported significant difference of WPAI among all
diagnoses. Absenteeism for patients with RA, AS and Ps was 8.39%, 10.79% and
14.90%. Presenteeism was 40.26% for patients with RA, which was greater by 7.29%
and 5.83% compared to AS and Ps patients. Patients with AS, RA and Ps reported
overall work productivity loss of 40.85%, 42.92% and 42.82%, respectively. Activity
impairments were approximately 50.00%. Average annual productivity costs per
one patient with RA, AS and Ps were €1913, €1809 and €1908, respectively. Produc-
tivity costs strongly correlated with PROs, whereas correlations with clinical pa-
rameters were weak. CONCLUSIONS: The productivity loss was almost the same
within all three diagnoses. HAQ, BASDAI in contrast to DAS28, BSA/PASI influenced
productivity costs. Average annual productivity costs per each patient were almost
€2000.
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DRUG USE PROFILE IN A RHEUMATOID ARTHRITIS PATIENT COHORT: A
BRAZILIAN HEALTH MANAGEMENT ORGANIZATION EXPERIENCE
Cantanheda CRDO, Simas HS, Dias QCP
Unimed-Rio Cooperativa de Trabalho Médico, Rio de Janeiro, Rio de Janeiro, BrazilRheumatoid
arthritis (RA) is a systemic autoimmune disease characterized by synovitis and joint erosions,
which affects around 1% of adult population worldwide. In Brazil, patients with moderate to
severe RA can be treated with biologic DMARDs infliximab, etanercept, adalimumab, abatacept
or tocilizumab. Patients who responded inadequately to previously biologic DMARDs can be
treated with rituximab.
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